We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > H3 Biomedicine

News List

Bristol-Myers, H3 Biomedicine explore RNA splicing drugs for cancer fiercebiotech
December 25, 2018
Bristol-Myers Squibb is tapping Eisai spinoff H3 Biomedicine and its RNA-splicing technology for a multiyear research partnership....
H3 Biomedicine Reports Discovery of Recurrent RNA Splicing Factor Mutations in Non-Hodgkin’s Lymphoma and Multiple Myeloma biospace
April 18, 2018
H3 Biomedicine Inc today announced novel findings from a comprehensive genomic analysis of 6,235 patients across 15 hematologic malignancies.
FDA grants orphan drug status to H3 Biomedicine’s cancer treatment H3B-8800 pharmaceutical-technology
August 17, 2017
H3 Biomedicine, a member of Eisai’s global Oncology Business Group, has received orphan drug designation from the US Food and Drug Administration (FDA) for its H3B-8800, a clinical compound used to treat patients with acute myelogenous leukaemia (AML) and